Fig. 2From: Design of the Prospective Real-world Outcomes Study of hepatic encephalopathy Patients’ Experience on Rifaximin-α (PROSPER): an observational study among 550 patientsTiming of entry into study, relative to overt HE episode. HE, hepatic encephalopathyBack to article page